Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial
Objective
To evaluate the orexin receptor antagonist suvorexant for reducing delirium in older adults at high risk for delirium after hospitalization.
Design and Participants
Double-blind, placebo-controlled, phase 3 randomized clinical trial conducted at 50 hospitals in Japan. Study population included Japanese adults aged 65 to 90 years at high risk for delirium and hospitalized for acute disease or elective surgery.
Intervention
Participants were randomized 1:1 to suvorexant (15 mg) or placebo taken at bedtime for up to 7 days while in the hospital.
Main Outcomes and Measures
Primary endpoint was the diagnosis of delirium according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria while participants were hospitalized. Treatment difference in the proportion of participants with delirium was analyzed.
Results
Study included 203 participants. Fewer participants taking suvorexant had delirium compared with placebo, but the difference was not statistically significant. Adverse events were similar between the 2 groups.
Conclusions and Relevance
Further studies are needed to determine whether suvorexant may be useful for reducing delirium in older adults at high risk for delirium after hospitalization.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04571944.
Clinical Trials and Practical Solutions
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
Value in Healthcare Operations
Streamlining operations is crucial in today’s healthcare environment. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
Enhancing Workflows with AI
By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routine. Learn more about how we can help at aidevmd.com.
